BioSpace News Archive

Encompass Health Corporation (NYSE: EHC) issued notice for redemption of all $700 million in outstanding principal balance of its 5.75% senior notes due 2024 (the “2024 Notes”)

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed John F. Crowley to its Board of Directors. Mr. Crowley is a well-established leader in biotech and pharmaceuticals and a visionary advocate for the advancement of treatments for people living with rare diseases. He joins Intellia’s board during a pivota

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced participation in two upcoming conferences focused on HBV. ICE-HBV Serum Biomarkers Virtual Workshop 2020 Panel: What are the virological and immunological gaps that need to be addressed? What biomarkers are most needed to

Real-World Population Representative of P atients Enrolled in GALACTIC-HF I ndicate a H igh- N eed, H igh- R isk P opulation with Heart Failure New Results from COSMIC-HF Show Treatment with Omecamtiv Mecarbil Associated with Improved Right Ventricular Function SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the Heart Failure Society of America (HFSA) Virtual An

-- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --

Hepion Pharmaceuticals, Inc. today announced the rollout of a proprietary artificial intelligence (“AI”), machine learning platform called, AI-POWR™.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX ® Pd, a new oral iron supplement formulation, by its subsidiary BioSyent Pharma Inc. FeraMAX ® Pd is a patented delivery system for the treatment of iron deficiency anemia and will be the foundation of future product developments. BioSyent Pharma has a deep expertise and experience in the iron deficiency anemia therapy and pre

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the execution of a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb (BMS) to investigate the combination of Zenith’s epigenetic therapy – BET inhibitor ZEN-3694 – with i

Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced the launch of the Sequel ® IIe System, the next instrument evolution based on the company’s Single Molecule, Real-Time (SMRT ® ) Sequencing technology. With increased computational capacity and on-instrument data processing, the new system can directly produce highly accurate long r

Blue Cross Blue Shield of Massachusetts (Blue Cross) is supporting state and national public health experts in encouraging flu vaccinations. A severe flu outbreak this winter, coupled with a resurgence of the coronavirus, would pose a serious threat to individual and public health, as well as the health care system.